URGN
Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
UroGen Pharma Ltd. (URGN)Equibles does not estimate personal net worth.
Get an email with a short summary when UroGen Pharma Ltd. publishes a filing, an earnings call transcript or a press release.
Get URGN alertsVincent Perrone is recorded as Head of Investor Relations at UroGen Pharma Ltd. (URGN). Vincent Perrone has spoken on 17 earnings calls across 1 company, most recently for UroGen Pharma Ltd. on November 4, 2026. UroGen Pharma Ltd. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at UroGen Pharma Ltd. includes Elizabeth Barrett (CEO and Board Member), Arie Belldegrun (Chairman and Board Member), Chris Degnan (CFO) and 7 others.
“Good morning, everyone, and welcome to Eurogen Pharma's third quarter, 2026 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30th, 2026.”
“Welcome to Urgent Pharma's second quarter, 2026 Financial Results and Business Update Conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30th, 2026.”
“Good morning everyone and welcome to your Eurogen Pharma's first quarter, 2026 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31st, 2026.”
“Good morning, everyone, and welcome to Eurogen Pharma's full year 2025 Financial Results and Business Update conference call. Earlier this morning, we issued two press releases.”
“Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2025 Financial Results and Business Update Conference Call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended September 30, 2025.”
URGN
Biotechnology · Healthcare
Head of Investor Relations